Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Open access
Wheeler, David C, Stefansson, Bergur V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z I, Chertow, Glenn M, Douthat, Walter, Dwyer, Jamie P, Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B, McMurray, John J V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D, Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C David, Langkilde, Anna Maria, Heerspink, Hiddo J L · 2020 · Nephrology Dialysis Transplantation

Abstract

Background: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Mean eGFR was 43.1 mL/min/1.73 m2 and median UACR was 949 mg/g (108 mg/mmol). Results: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1 mL/min/1.73 m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions: Participants with a wide range of underlying kidney diseases receiving renin–angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2–4 and increased albuminuria, with and without T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfaa234

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 14

  1. Thomson, 2012, Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat, Am J Physiol Regul Integr Comp Physiol, 302, R75, 10.1152/ajpregu.00357.2011 · DOI · Paper page
  2. Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 · DOI · Paper page
  3. 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 · DOI · Paper page
  4. Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 · DOI · Paper page
  5. Heerspink, 2020, Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial, Nephrol Dial Transplant, 35, 274, 10.1093/ndt/gfz290 · DOI · Paper page
  6. Heerspink, 2018, Rationale and protocol of the study of diabetic nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy, Diabetes Obes Metab, 20, 1369, 10.1111/dom.13245 · DOI
  7. Lv, 2017, Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial, JAMA, 318, 432, 10.1001/jama.2017.9362 · DOI · Paper page
  8. Barratt, 2019, Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial), Kidney Int Rep, 4, 1633, 10.1016/j.ekir.2019.08.007 · DOI
  9. Heerspink, 2019, Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial, Lancet, 393, 1937, 10.1016/S0140-6736(19)30772-X · DOI · Paper page
  10. Lambers Heerspink, 2014, Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT, Am J Kidney Dis, 63, 244, 10.1053/j.ajkd.2013.09.016 · DOI · Paper page
  11. Sharma, 2013, The modern spectrum of renal biopsy findings in patients with diabetes, Clin J Am Soc Nephrol, 8, 1718, 10.2215/CJN.02510213 · DOI · Paper page
  12. Trachtman, 2018, DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS, J Am Soc Nephrol, 29, 2745, 10.1681/ASN.2018010091 · doi:10.1681/asn.2018010091
  13. Lazarus, 2018, Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study, JAMA Intern Med, 178, 903, 10.1001/jamainternmed.2018.0292 · DOI · Paper page
  14. Heerspink, 2018, Baseline characteristics and enrichment results from the SONAR trial, Diabetes Obes Metab, 20, 1829, 10.1111/dom.13315 · DOI

Cited by

See all 194

Metadata

Authors
Wheeler, D. C., Stefansson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., Furuland, H., Górriz, J. L., Greene, T., Haller, H., Hou, F. F., Kang, S.-W., Isidto, R., Khullar, D., Mark, P. B., McMurray, J. J. V., Kashihara, N., Nowicki, M., Persson, F., Correa-Rotter, R., Rossing, P., Toto, R. D., Umanath, K., Van Bui, P., Wittmann, I., Lindberg, M., Sjöström, C. D., Langkilde, A. M., & Heerspink, H. J. L.
Venue
Nephrology Dialysis Transplantation
Published
2020-08-30
Volume
35
Issue
10
Pages
1700-1711
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W3081745704
Cited by
194
References
12
FWCI
16.99
Type
journal article
Language
en
Open access
hybrid
Funders
AstraZeneca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. https://app.cochat.ai/papers/10.1093/ndt/gfaa234
The paper
Wheeler, D. C., Stefansson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., Furuland, H., Górriz, J. L., Greene, T., Haller, H., Hou, F. F., Kang, S.-W., Isidto, R., Khullar, D., Mark, P. B., . . . Heerspink, H. J. L. (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaa234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.